Journal of Cancer Research and Therapeutics Close
 

Figure 4: Q1 aggregate and dead cells, Q2 late apoptotic cells, Q3 live cells, and Q4 early apoptotic cells. (a) Cystic fibrosis pancreatic adenocarcinoma cell line-1 48 h control cells (Q1: 0.9%, Q2: 0.2%, Q3: 98%, and Q4: 0.9%). (b) Cells treated with danusertib for 48 h (Q1: 0.9%, Q2: 4.3%, Q3: 73.4%, and Q4: 21.3%)

Figure 4: Q1 aggregate and dead cells, Q2 late apoptotic cells, Q3 live cells, and Q4 early apoptotic cells. (a) Cystic fibrosis pancreatic adenocarcinoma cell line-1 48 h control cells (Q1: 0.9%, Q2: 0.2%, Q3: 98%, and Q4: 0.9%). (b) Cells treated with danusertib for 48 h (Q1: 0.9%, Q2: 4.3%, Q3: 73.4%, and Q4: 21.3%)